.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after an average consequence of 11 months, individuals with metastatic intestinal tumors that acquired biomarker-matched treatments based upon flowing tumor DNA profiling revealed a more significant medical advantage than those obtaining unequaled therapy.